PERSON – Page 36

Alfasigma’s PBC Treatment Ocaliva to Face FDA Advisory Committee in September

9 months ago talkbio0Tagged Advisory Committees, Alfasigma, Biliary Cholangitis, Liver diseases, Ocaliva, PBC, Primary Biliary Cholangitis, United States Food and Drug Administration

Alfasigma, Ocaliva, PBC, FDA advisory committee, primary biliary cholangitis, liver disease treatment

Apellis and Sobi Achieve Significant Breakthrough in Phase 3 Trial for Rare Kidney Disease Treatment

9 months ago talkbio0Tagged Agencies, Apellis, Approved, C3 glomerulopathy, Clinical Research, European (ethnic group), membranoproliferative glomerulonephritis, Proteinuria, Sobi, United States Food and Drug Administration

Apellis Pharmaceuticals, Sobi, pegcetacoplan, Phase 3 VALIANT study, C3 glomerulopathy, primary immune complex membranoproliferative glomerulonephritis, proteinuria reduction, kidney disease treatment, FDA approval, European Medicines Agency

Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals

9 months ago talkbio0Tagged Adult, Aeterna Zentaris, Biological Factors, Biopharma, Changing, COSCIENS, development aspects, Diagnostic tests, Macrilen, rebranding, Somatotropin deficiency

Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency

Stoke Therapeutics Advances Dravet Syndrome Drug to Phase III Trials After FDA Lifts Partial Clinical Hold

9 months ago talkbio0Tagged Activator, Infantile Severe Myoclonic Epilepsy, orphan drug designation, pediatric disease designation, Phase 3 Clinical Trials, SCN1A gene, Stoke, United States Food and Drug Administration, Zorevunersen

Stoke Therapeutics, Dravet syndrome, Phase III trials, FDA, zorevunersen, SCN1A activator, orphan drug designation, rare pediatric disease designation